ImmunityBio Stock Trading Higher On Updates From Bladder Cancer Trials: Details
1. ImmunityBio is advancing FDA talks on NMIBC and NSCLC treatments. 2. ImmunityBio plans sBLA submission in 2025 for NMIBC treatment. 3. Positive clinical results showed 55% disease-free rate at 12 months. 4. Collaborating with Serum Institute for alternative BCG source in 2025. 5. IBRX stock rose 18.6% following the announcements.